CONSORT-EHEALTH (V 1.6.1) -Submission/Publication Form

The CONSORT-EHEALTH checklist is intended for authors of randomized trials evaluating web-based and Internet-based applications/interventions, including mobile interventions, electronic games (incl multiplayer games), social media, certain telehealth applications, and other interactive and/or networked electronic applications. Some of the items (e.g. all subitems under item 5 - description of the intervention) may also be applicable for other study designs.

The goal of the CONSORT EHEALTH checklist and guideline is to be a) a guide for reporting for authors of RCTs, b) to form a basis for appraisal of an ehealth trial (in terms of validity)

CONSORT-EHEALTH items/subitems are MANDATORY reporting items for studies published in the Journal of Medical Internet Research and other journals / scientific societies endorsing the checklist.

Items numbered 1., 2., 3., 4a., 4b etc are original CONSORT or CONSORT-NPT (nonpharmacologic treatment) items. Items with Roman numerals (i., ii, iii, iv etc.) are CONSORT-EHEALTH extensions/clarifications.

As the CONSORT-EHEALTH checklist is still considered in a formative stage, we would ask that you also RATE ON A SCALE OF 1-5 how important/useful you feel each item is FOR THE PURPOSE OF THE CHECKLIST and reporting guideline (optional).

Mandatory reporting items are marked with a red *.

In the textboxes, either copy & paste the relevant sections from your manuscript into this form - please include any quotes from your manuscript in QUOTATION MARKS, or answer directly by providing additional information not in the manuscript, or elaborating on why the item was not relevant for this study.

YOUR ANSWERS WILL BE PUBLISHED AS A SUPPLEMENTARY FILE TO YOUR PUBLICATION IN JMIR AND ARE CONSIDERED PART OF YOUR PUBLICATION (IF ACCEPTED). Please fill in these questions diligently. Information will not be copyedited, so please use proper spelling and grammar, use correct capitalization, and avoid abbreviations.

DO NOT FORGET TO SAVE AS PDF _AND_ CLICK THE SUBMIT BUTTON SO YOUR ANSWERS ARE IN OUR DATABASE !!!

Citation Suggestion (if you append the pdf as Appendix we suggest to cite this paper in the caption):

Eysenbach G, CONSORT-EHEALTH Group CONSORT-EHEALTH: Improving and Standardizing Evaluation Reports of Web-based and Mobile Health Interventions J Med Internet Res 2011;13(4):e126 URL: <u>http://www.jmir.org/2011/4/e126/</u> doi: 10.2196/jmir.1923 PMID: 22209829

* Required

Your name * First Last

Cindy Blair

Primary Affiliation (short), City, Country * University of Toronto, Toronto, Canada

University of New Mexico, Albuquerque, New N

Your e-mail address * abc@gmail.com

CiBlair@salud.unm.edu

Title of your manuscript * Provide the (draft) title of your manuscript.

А

home-based mHealth intervention to replace sedentary time with light

•

Name of your App/Software/Intervention *

If there is a short and a long/alternate name, write the short name first and add the long name in brackets.

Jawbone UP2

Evaluated Version (if any)

e.g. "V1", "Release 2017-03-01", "Version 2.0.27913"

Your answer

Language(s) *

What language is the intervention/app in? If multiple languages are available, separate by comma (e.g. "English, French")

English

URL of your Intervention Website or App

e.g. a direct link to the mobile app on app in appstore (itunes, Google Play), or URL of the website. If the intervention is a DVD or hardware, you can also link to an Amazon page.

https://play.google.com/store/apps/details?id

URL of an image/screenshot (optional)

Your answer

Accessibility *

Can an enduser access the intervention presently?

-) access is free and open
-) access only for special usergroups, not open
-) access is open to everyone, but requires payment/subscription/in-app purchases
-) app/intervention no longer accessible
- Other: Jawbone went out of business; do not recomment this activity monitor or app

Primary Medical Indication/Disease/Condition *

e.g. "Stress", "Diabetes", or define the target group in brackets after the condition, e.g. "Autism (Parents of children with)", "Alzheimers (Informal Caregivers of)"

Cancer Survivor

Primary Outcomes measured in trial *

comma-separated list of primary outcomes reported in the trial

feasibility (recruitment, retention, safety, satisf

Secondary/other outcomes

Are there any other outcomes the intervention is expected to affect?

light-intensity stepping, moderate-intensity stepping, physical performance, quality of life, pain, fatigue

Recommended "Dose" * What do the instructions for users say on how often the app should be used?
O Approximately Daily
O Approximately Weekly
O Approximately Monthly
O Approximately Yearly
O "as needed"
O Other:

Approx. Percentage of Users (starters) still using the app as recommended after 3 months *


- unknown / not evaluated
- 0-10%
- 11-20%
- 21-30%
- 31-40%
- 41-50%
- 51-60%
- 61-70%
- 71%-80%
- 81-90%
- 91-100%
- O Other:

Overall, was the app/intervention effective? *
O yes: all primary outcomes were significantly better in intervention group vs control
O partly: SOME primary outcomes were significantly better in intervention group vs control
o statistically significant difference between control and intervention
O potentially harmful: control was significantly better than intervention in one or more outcomes
O inconclusive: more research is needed
O Other:

Article Preparation Status/Stage *	
At which stage in your article preparation are you currently (at the time you fill in this form)	
not submitted yet - in early draft status	
O not submitted yet - in late draft status, just before submission	
submitted to a journal but not reviewed yet	
automitted to a journal and after reasiving initial reviewer comments	
Submitted to a journal and after receiving initial reviewer comments	
Submitted to a journal and accepted, but not published yet	
O published	
O Other:	
\sim	

Journal *

If you already know where you will submit this paper (or if it is already submitted), please provide the journal name (if it is not JMIR, provide the journal name under "other")



Is this a full powered effectiveness trial or a pilot/feasibility trial? *
Pilot/feasibility
O Fully powered

Manuscript tracking number *

If this is a JMIR submission, please provide the manuscript tracking number under "other" (The ms tracking number can be found in the submission acknowledgement email, or when you login as author in JMIR. If the paper is already published in JMIR, then the ms tracking number is the four-digit number at the end of the DOI, to be found at the bottom of each published article in JMIR)

) no ms number (yet) / not (yet) submitted to / published in JMIR

• Other: 18819

TITLE AND ABSTRACT

1a) TITLE: Identification as a randomized trial in the title

1a) Does your paper address CONSORT item 1a? * I.e does the title contain the phrase "Randomized Controlled Trial"? (if not, explain the reason under "other")	
yes	
O Other:	

1a-i) Identify the mode of delivery in the title


Identify the mode of delivery. Preferably use "web-based" and/or "mobile" and/or "electronic game" in the title. Avoid ambiguous terms like "online", "virtual", "interactive". Use "Internet-based" only if Intervention includes non-web-based Internet components (e.g. email), use "computer-based" or "electronic" only if offline products are used. Use "virtual" only in the context of "virtual reality" (3-D worlds). Use "online" only in the context of "online support groups". Complement or substitute product names with broader terms for the class of products (such as "mobile" or "smart phone" instead of "iphone"), especially if the application runs on different platforms.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

Does your paper address subitem 1a-i? *

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"mHealth intervention"



Does your paper address subitem 1a-ii?

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Non-web

based components were not mentioned in the title since there were two intervention groups: one with only tech support; one withe tech support

1a-iii) Primary condition or target group in the title

Mention primary condition or target group in the title, if any (e.g., "for children with Type I Diabetes") Example: A Web-based and Mobile Intervention with Telephone Support for Children with Type I Diabetes: Randomized Controlled Trial



Does your paper address subitem 1a-iii? *

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"older cancer survivors"

1b) ABSTRACT: Structured summary of trial design, methods, results, and


conclusions

NPT extension: Description of experimental treatment, comparator, care providers, centers, and blinding status.

1b-i) Key features/functionalities/components of the intervention and

comparator in the METHODS section of the ABSTRACT

Mention key features/functionalities/components of the intervention and comparator in the abstract. If possible, also mention theories and principles used for designing the site. Keep in mind the needs of systematic reviewers and indexers by including important synonyms. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)



Does your paper address subitem 1b-i? *

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Fifty-four

cancer survivors (60-84 years) were randomized in a 1:1:1 allocation to the Tech Support intervention group, Tech Support plus Health Coaching intervention group, or waitlist control. Intervention participants received a Jawbone UP2 activity monitor to use with their smart phone

1b-ii) Level of human involvement in the METHODS section of the ABSTRACT

Clarify the level of human involvement in the abstract, e.g., use phrases like "fully automated" vs. "therapist/nurse/care provider/physician-assisted" (mention number and expertise of providers involved, if any). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential


Does your paper address subitem 1b-ii?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Tech support and health coaching were provided via 5 telephone calls during the 16-week intervention."

1b-iii) Open vs. closed, web-based (self-assessment) vs. face-to-face assessments in the METHODS section of the ABSTRACT

Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic or a closed online user group (closed usergroup trial), and clarify if this was a purely web-based trial, or there were face-to-face components (as part of the intervention or for assessment). Clearly say if outcomes were self-assessed through questionnaires (as common in web-based trials). Note: In traditional offline trials, an open trial (open-label trial) is a type of clinical trial in which both the researchers and participants know which treatment is being administered. To avoid confusion, use "blinded" or "unblinded" to indicated the level of blinding instead of "open", as "open" in web-based trials usually refers to "open access" (i.e. participants can self-enrol). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)



Does your paper address subitem 1b-iii?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Sedentary behavior and physical activity were objectively measured using an

•

1b-iv) RESULTS section in abstract must contain use data							
Report number of participants enrolled/assessed in each group, the use/uptake of the intervention (e.g., attrition/adherence metrics, use over time, number of logins etc.), in addition to primary/secondary outcomes. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)							
	1	2	3	4	5		
subitem not at all important	0	0	0	0	0	essential	

Does your paper address subitem 1b-iv?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Fifty-four cancer survivors (60-84 years) were randomized ..."; "Forty-seven participants completed the trial (87% retained)."

1b-v) CONCLUSIONS/DISCUSSION in abstract for negative trials

Conclusions/Discussions in abstract for negative trials: Discuss the primary outcome - if the trial is negative (primary outcome not changed), and the intervention was not used, discuss whether negative results are attributable to lack of uptake and discuss reasons. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

Does your paper address subitem 1b-v?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Α

home-based mHealth program to disrupt and replace sedentary time with stepping was feasible in and acceptable to older cancer survivors. The greater improvement in stepping compared to sitting and standing

INTRODUCTION

2a) In INTRODUCTION: Scientific background and explanation of rationale

2a-i) Problem and the type of system/solution

Describe the problem and the type of system/solution that is object of the study: intended as stand-alone intervention vs. incorporated in broader health care program? Intended for a particular patient population? Goals of the intervention, e.g., being more cost-effective to other interventions, replace or complement other solutions? (Note: Details about the intervention are provided in "Methods" under 5)

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

Does your paper address subitem 2a-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The

purpose of this study was to examine the feasibility, acceptability and preliminary efficacy of a mHealth intervention to replace and disrupt

2a-ii) Scientific background, rationale: What is known about the (type of) system

Scientific background, rationale: What is known about the (type of) system that is the object of the study (be sure to discuss the use of similar systems for other conditions/diagnoses, if appropiate), motivation for the study, i.e. what are the reasons for and what is the context for this specific study, from which stakeholder viewpoint is the study performed, potential impact of findings [2]. Briefly justify the choice of the comparator.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

Does your paper address subitem 2a-ii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The

16-week intervention used the Jawbone UP2 activity monitor and associated smartphone app to promote awareness and enable

2b) In INTRODUCTION: Specific objectives or hypotheses

Does your paper address CONSORT subitem 2b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"We

hypothesized that (1) we would meet the accrual target of 60 inactive, older cancer survivors within 8 months, retain 80% of the enrolled participants, and achieve 80% adherence/fidelity to the intervention, and (2) a mHealth approach would be effective in helping older cancer survivors to replace and disrupt sedentary time with intermittent bouts

METHODS

3a) Description of trial design (such as parallel, factorial) including allocation ratio

Does your paper address CONSORT subitem 3a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Participants were block randomized with equal allocation to three arms (Tech Support, Tech Support plus Health Coaching, or modified Waitlist

3b) Important changes to methods after trial commencement (such as eligibility criteria), with reasons

Does your paper address CONSORT subitem 3b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Due

to the major malfunctions with the Jawbone UP2 monitors during the

3b-i) Bug fixes, Downtimes, Content Changes

Bug fixes, Downtimes, Content Changes: ehealth systems are often dynamic systems. A description of changes to methods therefore also includes important changes made on the intervention or comparator during the trial (e.g., major bug fixes or changes in the functionality or content) (5-iii) and other "unexpected events" that may have influenced study design such as staff changes, system failures/downtimes, etc. [2].

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

Does your paper address subitem 3b-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Problems

with Jawbone UP2 monitors During the intervention, the Jawbone UP2 wristbands started to fail (i.e., losing settings, losing connection with app, not syncing data, etc.), affecting 13 out of 36 intervention group participants. New Jawbone UP2 wristbands were purchased through other sources, but many of these wristbands also failed. We were able to buy and test enough UP2 wristbands to replace the failed units for the intervention group participants. Given these major issues and lack of support from Jawbone, some of the waitlist control participants were provided with a Fitbit Alta at the end of the 16-week study. This product was similar to the


4a) Eligibility criteria for participants

Does your paper address CONSORT subitem 4a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Eligibility

criteria for the feasibility study included: (1) men and women aged 60 years and older, 2) diagnosed with an invasive, local or regionally staged cancer within the past 7 years and completed primary treatment (surgery, radiation, chemotherapy), 3) owned a smart phone capable of running the Jawbone UP2 smartphone app, 4) willingness to be randomized to any of the three study arms, attend two clinic visits, and wear activity monitors, 5) able to read, speak, & understand English, 6) living independently and capable of walking three blocks (approximately 1/4 mile or 1300 steps) without an assistive device (e.g., cane, walker), 7) self-reported sedentary time (during waking hours) ≥ 6 hours/day, 8) not currently participating in a program to decrease sedentary time or increase physical activity, 9) no paid employment or volunteer position for more than 20 hours per week (to avoid potential confounding by occupational activity/inactivity), 10) no severe impairments (in seeing or hearing) or pre-existing medical limitations for engaging in daily light physical activity (e.g., severe orthopedic conditions, pending hip/knee replacement, dementia, oxygen dependent),



Does your paper address subitem 4a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

То

be eligible, the participants needed to own a smartphone capable of running the Jawbone UP app, and be willing to wear the Jawbone UP2 wrist monitor. However, the level of comfort with their smartphone and using technology was not an ineligibility criteria as tech support was

4a-ii) Open vs. closed, web-based vs. face-to-face assessments:

Open vs. closed, web-based vs. face-to-face assessments: Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic, and clarify if this was a purely webbased trial, or there were face-to-face components (as part of the intervention or for assessment), i.e., to what degree got the study team to know the participant. In online-only trials, clarify if participants were quasi-anonymous and whether having multiple identities was possible or whether technical or logistical measures (e.g., cookies, email confirmation, phone calls) were used to detect/prevent these.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

Does your paper address subitem 4a-ii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The

population-based New Mexico Tumor Registry, a founding member of the Surveillance, Epidemiology, and End Results (SEER) Program [47], was used as the primary source for identifying potential study participants.

4a-iii) Information giving during recruitment

Information given during recruitment. Specify how participants were briefed for recruitment and in the informed consent procedures (e.g., publish the informed consent documentation as appendix, see also item X26), as this information may have an effect on user self-selection, user expectation and may also bias results.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

Does your paper address subitem 4a-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Potential


participants were then mailed a letter explaining the study and a consent form. One week later, staff telephoned to discuss the study,

4b) Settings and locations where the data were collected

Does your paper address CONSORT subitem 4b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Clinic visits were conducted at the University of New Mexico Clinical and Translational Science Center. "



Does your paper address subitem 4b-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

There

were no online questionnaires. Participants completed surveys at home

4b-ii) Report how institutional affiliations are displayed

Report how institutional affiliations are displayed to potential participants [on ehealth media], as affiliations with prestigious hospitals or universities may affect volunteer rates, use, and reactions with regards to an intervention.(Not a required item – describe only if this may bias results)

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

Does your paper address subitem 4b-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The


institutional affiliation, the University of New Mexico Comprehensive

5) The interventions for each group with sufficient details to allow replication, including how and when they were actually administered

5-i) Mention names, credential, affiliations of the developers, sponsors, and

owners

Mention names, credential, affiliations of the developers, sponsors, and owners [6] (if authors/evaluators are owners or developer of the software, this needs to be declared in a "Conflict of interest" section or mentioned elsewhere in the manuscript).



Does your paper address subitem 5-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The

intervention used a consumer wearable activity monitor (Jawbone UP2TM wrist band) that paired with a smartphone app to promote awareness and enable self-monitoring of both physical activity (e.g., steps per day)

5-ii) Describe the history/development process

Describe the history/development process of the application and previous formative evaluations (e.g., focus groups, usability testing), as these will have an impact on adoption/use rates and help with interpreting results.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

Does your paper address subitem 5-ii? Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study									
The Jawbone UP2 activity monitor was readily available to consumers until the company went out of business. The associated UP app was available									
5-iii) Revisions and updating Revisions and updating. Clearly ment (and comparator, if applicable) evalua during the evaluation process, or whe Describe dynamic components such a the replicability of the intervention (fo	ated, or de ther the c as news f	escribe wh levelopme eeds or ch	ether the i nt and/or anging co	interventic content wa	n underwe as "frozen"	ent major changes during the trial.			
	1	2	3	4	5				
subitem not at all important	0	0	0	0	0	essential			

Does your paper address subitem 5-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The UP2 app was evaluated between August 2016 and July 2017.

5-iv) Quality assurance meth	nods						
Provide information on quality assurance methods to ensure accuracy and quality of information provided [1], if applicable.							
	1	2	3	4	5		
subitem not at all important	0	0	0	0	0	essential	

Does your paper address subitem 5-iv?								
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study								
This intervention study used a consumer wearable and associated free								
5-v) Ensure replicability by publishing the source code, and/or providing screenshots/screen-capture video, and/or providing flowcharts of the algorithms used Ensure replicability by publishing the source code, and/or providing screenshots/screen-capture video, and/or providing flowcharts of the algorithms used. Replicability (i.e., other researchers should in principle be able to replicate the study) is a hallmark of scientific reporting.								
	1	2	3	4	5			
subitem not at all important	0	0	0	0	0	essential		

Does your paper address subitem 5-v?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"ActivPAL3TM

data were downloaded using the activPAL software (version 7; PAL Technologies Limited). The event files (start/stop time for sitting/lying, standing, and stepping) were processed using the activpalProcessing R package (version 1.0.2). To be included in analyses, a participant needed at least one valid day of ActivPAL3TM data from baseline. Due to the large variability in the within- and between-person average number of awake/wear hours, all activPAL metrics

5-vi) Digital preservation

Digital preservation: Provide the URL of the application, but as the intervention is likely to change or disappear over the course of the years; also make sure the intervention is archived (Internet Archive, <u>webcitation.org</u>, and/or publishing the source code or screenshots/videos alongside the article). As pages behind login screens cannot be archived, consider creating demo pages which are accessible without login.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

Does your paper address subitem 5-vi?


Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Jawbone

went out of business. Individuals interested in consumer wearable

5-vii) Access

Access: Describe how participants accessed the application, in what setting/context, if they had to pay (or were paid) or not, whether they had to be a member of specific group. If known, describe how participants obtained "access to the platform and Internet" [1]. To ensure access for editors/reviewers/readers, consider to provide a "backdoor" login account or demo mode for reviewers/readers to explore the application (also important for archiving purposes, see vi).



Does your paper address subitem 5-vii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Participants

received their Jawbone UP activity monitor and detailed instructions in the mail. Their tech support or health coach followed up with a telephone call to assist with the installation and setup of the activity

5-viii) Mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework

Describe mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework [6] used to design them (instructional strategy [1], behaviour change techniques, persuasive features, etc., see e.g., [7, 8] for terminology). This includes an in-depth description of the content (including where it is coming from and who developed it) [1]," whether [and how] it is tailored to individual circumstances and allows users to track their progress and receive feedback" [6]. This also includes a description of communication delivery channels and – if computer-mediated communication is a component – whether communication was synchronous or asynchronous [6]. It also includes information on presentation strategies [1], including page design principles, average amount of text on pages, presence of hyperlinks to other resources, etc. [1].



Does your paper address subitem 5-viii? *


Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The

theoretical framework used to guide this intervention was Social Cognitive Theory [48, 49], based on the following concepts for promoting behavioral change: (a) self-efficacy by encouraging incremental goal setting (steps/day, "idle alert" setting), (b) skills development and behavioral capability by providing participants with instructions on using the Jawbone UP2TM activity monitor and mobile app to track activity and update goals, (c) self-monitoring of activity and inactivity by using the mobile app to review daily progress and weekly

5-ix) Describe use parameters

Describe use parameters (e.g., intended "doses" and optimal timing for use). Clarify what instructions or recommendations were given to the user, e.g., regarding timing, frequency, heaviness of use, if any, or was the intervention used ad libitum.



Does your paper address subitem 5-ix?


Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The

participants were instructed to wear the monitor during waking hours and were encouraged to track their activity at least once a day by viewing their results on the app, which included a daily summary of total steps, total and longest active time, and longest idle time. To promote gradual and sustained change in light physical activity, participants were asked to increase the number of steps per day (above their individual baseline level, established in week three during weeks

5-x) Clarify the level of human involvement

Clarify the level of human involvement (care providers or health professionals, also technical assistance) in the e-intervention or as co-intervention (detail number and expertise of professionals involved, if any, as well as "type of assistance offered, the timing and frequency of the support, how it is initiated, and the medium by which the assistance is delivered". It may be necessary to distinguish between the level of human involvement required for the trial, and the level of human involvement required for a routine application outside of a RCT setting (discuss under item 21 – generalizability).



Does your paper address subitem 5-x?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Tech

Support and Health Coaching Calls

During the first telephone call, the tech support and health coaches reviewed the ActivPAL3TM baseline summary data (total and percentage of time spent sedentary, standing, and stepping for best and worst day) with the participant, and discussed the importance of reducing sedentary time, especially prolonged periods of inactivity. Additional telephone calls (15-20 minutes) were made during weeks 4, 6, 10, and 12 to verify completion or to assist participants with changing the steps per day goal and "idle alert" setting on their app (if needed). Tech support coaches provided support related only to the technology (Jawbone UP2 activity monitor and/or smartphone app), including trouble shooting of technical issues. In contrast, health coaches provided additional support to help their participants identify a list of light physical

5-xi) Report any prompts/reminders used

Report any prompts/reminders used: Clarify if there were prompts (letters, emails, phone calls, SMS) to use the application, what triggered them, frequency etc. It may be necessary to distinguish between the level of prompts/reminders required for the trial, and the level of prompts/reminders for a routine application outside of a RCT setting (discuss under item 21 – generalizability).



Does your paper address subitem 5-xi? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The

Jawbone UP2 app provided reminders to move (every 30 minutes) and

5-xii) Describe any co-interventions (incl. training/support)

Describe any co-interventions (incl. training/support): Clearly state any interventions that are provided in addition to the targeted eHealth intervention, as ehealth intervention may not be designed as stand-alone intervention. This includes training sessions and support [1]. It may be necessary to distinguish between the level of training required for the trial, and the level of training for a routine application outside of a RCT setting (discuss under item 21 – generalizability.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

Does your paper address subitem 5-xii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not applicable

6a) Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed

Does your paper address CONSORT subitem 6a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Primary

outcomes

As this was a feasibility and acceptability study, the outcomes related to recruitment, retention, and adherence rates, adverse events, and satisfaction with the program. Success of the program was determined by achievement of the following goals: 1) to recruit 60 older cancer survivors, 2) to retain 80% of the sample; 3) to achieve 80% adherence to the intervention; 4) to have no moderate or serious adverse events due to the intervention; and 5) to achieve high satisfaction rates with the intervention.

The behavioral outcomes of interest were change in total sedentary time (average minutes per day) and number of breaks from sitting (average breaks per day). Since the opportunity to interrupt sitting with standing or stepping is dependent on the amount of sedentary time, the break ratio was also calculated. The break ratio was defined as the number of absolute breaks divided by the total minutes of sedentary time. "

"Secondary outcomes

Objectively measured secondary outcomes included physical performance and physical activity. The Short Physical Performance Battery (SPPB) includes tests of standing balance, walking speed (timed 8-ft walk at usual speed), and lower body strength (time to rise from a chair 5 times). Scores range from zero (not attempted) to four (highest score) for each test, for a total score ranging from zero to 12. This battery has strong predictive validity and is responsive to change [6, 58].

The activPAL accelerometer was used to assess change in the number of prolonged sedentary bouts, total minutes spent in sedentary bouts, number of steps per day, and minutes of light- and moderate-intensity physical activity (stepping). A prolonged sedentary bout was defined as 30 or more continuous minutes in a seated or lying position. Light physical activity was defined as stepping at a cadence equivalent to 1.5 to 3.0 METs. A Metabolic Equivalents (MET) is a multiple of resting energy expenditure. With resting (sitting quietly) energy expenditure defined as 1 MET, a 3-MET activity expends three times the energy of rest while a 5-MET activity expends five times the energy of rest. Standing is also considered a light-intensity physical activity, and was reported separately from light stepping. Moderate-intensity physical activity was similarly defined, but with MET values at 3.0 or greater.

The Medical Health Outcomes Study Short Form 36-item survey (SF36, version 2) was used to assess health related QOL. The SF36 includes eight individual scale scores and two component summary scores for

6a-i) Online questionnaires: describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were designed/deployed							
If outcomes were obtained through online questionnaires, describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were designed/deployed [9].							
	1	0	0	4	-		
	I	2	3	4	5		
subitem not at all important	0	0	0	0	0	essential	

Does your paper address subitem 6a-i? Copy and paste relevant sections from manuscript text	
Not applicable	

6a-ii) Describe whether and how "use" (including intensity of use/dosage) was defined/measured/monitored

Describe whether and how "use" (including intensity of use/dosage) was defined/measured/monitored (logins, logfile analysis, etc.). Use/adoption metrics are important process outcomes that should be reported in any ehealth trial.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

Does your paper address subitem 6a-ii?

Copy and paste relevant sections from manuscript text

We were not able to capture when and how the participants used their UP2 smartphone app.

6a-iii) Describe whether, hov was obtained	v, and w	hen qua	alitative	feedbad	ck from	participants
Describe whether, how, and when qua emails, feedback forms, interviews, fo			om particij	oants was	obtained (e.g., through
	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

Does your paper address subitem 6a-iii? Copy and paste relevant sections from manuscript text

Qualitative feedback regarding the intervention was not obtained until 2 years later, and is not part of this report.

6b) Any changes to trial outcomes after the trial commenced, with reasons

Does your paper address CONSORT subitem 6b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The accrual goal was reduced from 60 to 54 due to technical problems

7a) How sample size was determined

NPT: When applicable, details of whether and how the clustering by care provides or centers was addressed

7a-i) Describe whether and h calculating the sample size Describe whether and how expected						
	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

Does your paper address subitem 7a-i?

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The

proposed pilot intervention was a feasibility and acceptability intervention and thus was not powered to detect small effect sizes for change in sedentary time and light physical activity (stepping). With 20 people per group, assuming a 2-sided alpha level of 0.05 and a standard

7b) When applicable, explanation of any interim analyses and stopping guidelines

Does your paper address CONSORT subitem 7b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Problems

with Jawbone UP2 monitors During the intervention, the Jawbone UP2 wristbands started to fail (i.e., losing settings, losing connection with app, not syncing data, etc.), affecting 13 out of 36 intervention group participants. New Jawbone UP2 wristbands were purchased through other sources, but many of these wristbands also failed. We were able to buy and test enough UP2 wristbands to replace the failed units for the intervention group participants. Given these major issues and lack of support from Jawbone, some of the waitlist control participants were provided with a Fitbit Alta at the end of the 16-week study. This product was similar to the Jawbone UP2 in that it provided an inactivity alert (reminder to move every hour), and allowed the user to set a step goal and track their

8a) Method used to generate the random allocation sequence NPT: When applicable, how care providers were allocated to each trial group

Does your paper address CONSORT subitem 8a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The random allocation sequence was created by a biostatistician on the study team.

8b) Type of randomisation; details of any restriction (such as blocking and block size)

Does your paper address CONSORT subitem 8b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Participants were block randomized with equal allocation to three arms (Tech Support, Tech Support plus Health Coaching, or modified Waitlist

9) Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned

Does your paper address CONSORT subitem 9? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Upon

receipt of the activPAL3 monitor, a member of the research team opened the next sequentially numbered sealed envelope (created by

10) Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions

Does your paper address CONSORT subitem 10? * Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study The

random allocation sequence was generated by a biostatistician. Several study team members were involved with recruiting study participants. The

11a) If done, who was blinded after assignment to interventions (for example,

participants, care providers, those assessing outcomes) and how

NPT: Whether or not administering co-interventions were blinded to group assignment

11a-i) Specify who was blinded, and who wasn't Specify who was blinded, and who wasn't. Usually, in web-based trials it is not possible to blind the participants [1, 3] (this should be clearly acknowledged), but it may be possible to blind outcome assessors, those doing data analysis or those administering co-interventions (if any). 1 2 3 4 5 subitem not at all important O O O O O essential

Does your paper address subitem 11a-i? * opy and paste relevant sections from the manuscript (include quotes in quotation m ndicate direct quotes from your manuscript), or elaborate on this item by providing ad nformation not in the ms, or briefly explain why the item is not applicable/relevant for	dditional
Siven	
he nature of the intervention, the study participants were not	
linded. Due to limited resources, the study team was not blinded as the	-

11a-ii) Discuss e.g., whether participants knew which intervention was the "intervention of interest" and which one was the "comparator" Informed consent procedures (4a-ii) can create biases and certain expectations - discuss e.g., whether participants knew which intervention was the "intervention of interest" and which one was the "comparator". 1 2 3 4 5 subitem not at all important O O O O O essential

Does your paper address subitem 11a-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Since

we utilized a condensed waitlist control group, participants were aware of the intervention versus the control. "The waitlist control group received the educational materials at the post-intervention follow-up

11b) If relevant, description of the similarity of interventions

(this item is usually not relevant for ehealth trials as it refers to similarity of a placebo or sham intervention to a active medication/intervention)

Does your paper address CONSORT subitem 11b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

II

Tech Support and Health Coaching Calls During the first telephone call, the tech support and health coaches reviewed the ActivPAL3TM baseline summary data (total and percentage of time spent sedentary, standing, and stepping for best and worst day) with the participant, and discussed the importance of reducing sedentary time, especially prolonged periods of inactivity. Additional telephone calls (15-20 minutes) were made during weeks 4, 6, 10, and 12 to verify completion or to assist participants with changing the steps per day goal and "idle alert" setting on their app (if needed). Tech support coaches provided support related only to the technology (Jawbone UP2 activity monitor and/or smartphone app), including trouble shooting of technical issues. In contrast, health coaches provided additional support to help their participants identify a list of light physical

12a) Statistical methods used to compare groups for primary and secondary outcomes

NPT: When applicable, details of whether and how the clustering by care providers or centers was addressed

Does your paper address CONSORT subitem 12a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Baseline

descriptive characteristics (mean ± SD, number (%)) were used to characterize the study population. Intent to treat analyses were conducted to evaluate the change in sedentary behavior metrics, and secondary outcomes. Linear mixed methods were used to estimate withinand between-group differences for each outcome. Each model included a fixed effect for group (tech support, health coaching, waitlist control), time (pre-, post-intervention), and group by time interaction. A subject-level random effect was included to account for the

12a-i) Imputation techniques to deal with attrition / missing values

Imputation techniques to deal with attrition / missing values: Not all participants will use the intervention/comparator as intended and attrition is typically high in ehealth trials. Specify how participants who did not use the application or dropped out from the trial were treated in the statistical analysis (a complete case analysis is strongly discouraged, and simple imputation techniques such as LOCF may also be problematic [4]).

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

Does your paper address subitem 12a-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No

imputation techniques were used. All participants with a baseline value

12b) Methods for additional analyses, such as subgroup analyses and adjusted analyses

information not in the ms, or briefly e		,				,		
"The results from per protocol analyses including only participants with								
X26) REB/IRB Approval and Ethical Considerations [recommended as subheading under "Methods"] (not a CONSORT item)								
X26-i) Comment on ethics co	ommitte		oval					
	1	2	3	4	5			
subitem not at all important	0	0	0	0	0	essential		
Does your paper address sub	oitem X	26-i?						
Copy and paste relevant sections from				otes in quo tem by pro				

x26-ii) Outline informed	l consent procedures
--------------------------	----------------------

Outline informed consent procedures e.g., if consent was obtained offline or online (how? Checkbox, etc.?), and what information was provided (see 4a-ii). See [6] for some items to be included in informed consent documents.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

Does your paper address subitem X26-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The

subject will be introduced to the study through a mailed letter of invitation. The consent form will accompany the letter, to allow the subject adequate time to read the materials before study staff follow-up with a phone call (7 to 10 days later) to review the study and answer any questions. If the subject expresses interest in the study, final eligibility will be assessed, and a baseline clinic visit will be scheduled. The subject may decline participation in the study or drop out of the study at any time. This will be stated both verbally (phone call, baseline clinic visit) and in writing (consent form). Upon arrival

X26-iii) Safety and security procedures. Safety and security procedures, incl. privacy considerations, and any steps taken to reduce the likelihood or detection of harm (e.g., education and training, availability of a hotline) 1 2 3 4 5 subitem not at all important O O O O O essential

Does your paper address subitem X26-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

There

were no provisions to monitor the data to ensure the safety of subjects

RESULTS

13a) For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome

NPT: The number of care providers or centers performing the intervention in each group and the number of patients treated by each care provider in each center

Does your paper address CONSORT subitem 13a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Fifty-four

cancer survivors (60-84 years) were randomized in a 1:1:1 allocation to the Tech Support intervention group, Tech Support plus Health Coaching intervention group, or waitlist control. Of the 54 cancer survivors enrolled in the study, data for the primary outcomes was available for

13b) For each group, losses and exclusions after randomisation, together with reasons

Does your paper address CONSORT subitem 13b? (NOTE: Preferably, this is shown in a CONSORT flow diagram) *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Of

the 54 cancer survivors enrolled in the study, data for the primary outcomes was available for 53 participants (1 monitor malfunction at baseline). As shown in Figure 2, six participants withdrew from the Tech Support group, one participant withdrew from the Health Coaching group. Reasons included: 5 – Withdrew (moved out of

13b-i) Attrition diagram Strongly recommended: An attrition diagram (e.g., proportion of participants still logging in or using the intervention/comparator in each group plotted over time, similar to a survival curve) or other figures or tables demonstrating usage/dose/engagement. 1 2 3 4 5 subitem not at all important O O O O O essential

Does your paper address subitem 13b-i?

Copy and paste relevant sections from the manuscript or cite the figure number if applicable (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Please see Figure 2

14a) Dates defining the periods of recruitment and follow-up

Does your paper address CONSORT subitem 14a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Recruitment began in July of 2016 and follow-up ended in July of 2017.

14a-i) Indicate if critical "secular events" fell into the study period								
Indicate if critical "secular events" fell into the study period, e.g., significant changes in Internet resources available or "changes in computer hardware or Internet delivery resources"								
	1	2	3	4	5			
subitem not at all important	0	0	0	0	0	essential		

Does your paper address subitem 14a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Other

than the major malfunctions with the Jawbone UP2 activity monitors

14b) Why the trial ended or was stopped (early)

Does your paper address CONSORT subitem 14b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The trial ended after the 54 enrolled participants completed the 16-week intervention.

15) A table showing baseline demographic and clinical characteristics for each

group

NPT: When applicable, a description of care providers (case volume, qualification, expertise, etc.) and centers (volume) in each group

Does your paper address CONSORT subitem 15? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Table 1

▲ ■

15-i) Report demographics associated with digital divide issues In ehealth trials it is particularly important to report demographics associated with digital divide issues, such as age, education, gender, social-economic status, computer/Internet/ehealth literacy of the participants, if known. 1 2 3 4 5 subitem not at all important O O O O O essential

Does your paper address subitem 15-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Table 1

16) For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups

16-i) Report multiple "denominators" and provide definitions

Report multiple "denominators" and provide definitions: Report N's (and effect sizes) "across a range of study participation [and use] thresholds" [1], e.g., N exposed, N consented, N used more than x times, N used more than y weeks, N participants "used" the intervention/comparator at specific pre-defined time points of interest (in absolute and relative numbers per group). Always clearly define "use" of the intervention.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

Does your paper address subitem 16-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not applicable

16-ii) Primary analysis should be intent-to-treat

Primary analysis should be intent-to-treat, secondary analyses could include comparing only "users", with the appropriate caveats that this is no longer a randomized sample (see 18-i).

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

Does your paper address subitem 16-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Intent to treat analyses were conducted to evaluate the change in sedentary behavior metrics, and secondary outcomes."

17a) For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)

Does your paper address CONSORT subitem 17a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Table 2

17a-i) Presentation of process outcomes such as metrics of use and intensity of

use

In addition to primary/secondary (clinical) outcomes, the presentation of process outcomes such as metrics of use and intensity of use (dose, exposure) and their operational definitions is critical. This does not only refer to metrics of attrition (13-b) (often a binary variable), but also to more continuous exposure metrics such as "average session length". These must be accompanied by a technical description how a metric like a "session" is defined (e.g., timeout after idle time) [1] (report under item 6a).

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

Does your paper address subitem 17a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Figure 3

17b) For binary outcomes, presentation of both absolute and relative effect sizes is recommended

Does your paper address CONSORT subitem 17b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not applicable; outcomes were continuous

18) Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory

Does your paper address CONSORT subitem 18? * Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study									
"The results from per protocol analyses including only participants with 🔹									
 18-i) Subgroup analysis of comparing only users A subgroup analysis of comparing only users is not uncommon in ehealth trials, but if done, it must be stressed that this is a self-selected sample and no longer an unbiased sample from a randomized trial (see 16-iii). 									
	1	2	3	4	5				
subitem not at all important	0	0	0	0	0	essential			

Does your paper address subitem 18-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The

results from per protocol analyses including only participants with

19) All important harms or unintended effects in each group

(for specific guidance see CONSORT for harms)

Does your paper address CONSORT subitem 19? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

There were no safety issues during the trial

19-i) Include privacy breaches, technical problems

Include privacy breaches, technical problems. This does not only include physical "harm" to participants, but also incidents such as perceived or real privacy breaches [1], technical problems, and other unexpected/unintended incidents. "Unintended effects" also includes unintended positive effects [2].

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

Does your paper address subitem 19-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not applicable

19-ii) Include qualitative feedback from participants or observations from

staff/researchers

Include qualitative feedback from participants or observations from staff/researchers, if available, on strengths and shortcomings of the application, especially if they point to unintended/unexpected effects or uses. This includes (if available) reasons for why people did or did not use the application as intended by the developers.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

Does your paper address subitem 19-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This paper reports on the primary and secondary outcomes of the trial and does not include qualitative feedback.

DISCUSSION

22) Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence

NPT: In addition, take into account the choice of the comparator, lack of or partial blinding, and unequal expertise of care providers or centers in each group

22-i) Restate study questions and summarize the answers suggested by the data, starting with primary outcomes and process outcomes (use)

Restate study questions and summarize the answers suggested by the data, starting with primary outcomes and process outcomes (use).

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

Does your paper address subitem 22-i?*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"This

study explored the feasibility, acceptability, and preliminary efficacy of a home-based mHealth intervention to disrupt and replace sedentary time with light physical activity (standing and stepping). There was much flexibility allowed to achieve this goal, i.e., no minimum bout duration (standing or stepping) nor intensity level (stepping) was provided to participants. The results suggest that most of the intervention group participants focused on the step goal, rather than standing more frequently. Furthermore, participants self-selected to accumulate steps in longer bouts and at a moderate vs. light-intensity. However, only the intervention group with additional health coaching

22-ii) Highlight unanswered new questions, suggest future research Highlight unanswered new questions, suggest future research.						1
	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

Does your paper address subitem 22-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"More


support for replacing rather than merely disrupting sedentary time with a suggested minimal bout duration may have been more helpful for individuals already taking frequent breaks from sitting."

"While many consumer activity trackers have several behavioral change techniques built-in to the tracker and/or the app, including Jawbone [67-69], accumulating evidence suggests that additional behavior change

20) Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses

20-i) Typical limitations in ehealth trials

Typical limitations in ehealth trials: Participants in ehealth trials are rarely blinded. Ehealth trials often look at a multiplicity of outcomes, increasing risk for a Type I error. Discuss biases due to non-use of the intervention/usability issues, biases through informed consent procedures, unexpected events.



Does your paper address subitem 20-i? *


Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Limitations

of our feasibility study include a potential for selection bias since smartphone ownership was an eligibility criterion. Additionally, individuals who enrolled were likely more motivated to change their inactivity. Recruitment was more difficult and time-consuming than anticipated, resulting in a low response rate. The use of a consumer activity monitor, in this case the Jawbone UP2, is both a limitation and a strength. We experienced substantial technical issues/failures with the device, affecting one-third of the intervention group, as the manufacturing company quit production, stopped providing support, and

21) Generalisability (external validity, applicability) of the trial findings

NPT: External validity of the trial findings according to the intervention, comparators, patients, and care providers or centers involved in the trial



Does your paper address subitem 21-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Larger trials are needed to assess generalizability to other populations.

21-ii) Discuss if there were elements in the RCT that would be different in a

routine application setting

Discuss if there were elements in the RCT that would be different in a routine application setting (e.g., prompts/reminders, more human involvement, training sessions or other co-interventions) and what impact the omission of these elements could have on use, adoption, or outcomes if the intervention is applied outside of a RCT setting.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

Does your paper address subitem 21-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not applicable

OTHER INFORMATION

23) Registration number and name of trial registry

Does your paper address CONSORT subitem 23? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

ClinicalTrials.gov NCT03632694 (https://clinicaltrials.gov/ct2/show/NCT03632694)

24) Where the full trial protocol can be accessed, if available

Does your paper address CONSORT subitem 24?*

Cite a Multimedia Appendix, other reference, or copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This paper includes the trial protocol as well as the results.

25) Sources of funding and other support (such as supply of drugs), role of funders

Does your paper address CONSORT subitem 25? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"This

research was supported by the American Cancer Society Institutional Review Grant (#IRG-14-187-19) and the University of New Mexico (UNM) Comprehensive Cancer Center Support Grant NCI P30CA118100 and the Behavioral Measurement and Population Sciences Shared Resource and the Biostatistics Shared Resource. This project was also supported by Contract HHSN261201800014I, Task Order HHSN26100001 from the National Cancer Institute. The content is solely the responsibility of the

X27) Conflicts of Interest (not a CONSORT item)

X27-i) State the relation of the study team towards the system being evaluated

In addition to the usual declaration of interests (financial or otherwise), also state the relation of the study team towards the system being evaluated, i.e., state if the authors/evaluators are distinct from or identical with the developers/sponsors of the intervention.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

Does your paper address subitem X27-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Conflicts of Interest None declared

About the CONSORT EHEALTH checklist

As a result of using this checklist, did you make changes in your manuscript? *

) yes, major changes

) yes, minor changes

🔵 no

What were the most important changes you made as a result of using this checklist?

Your answer

How much time did you spend on going through the checklist INCLUDING making changes in your manuscript *

2 hours

As a result of using this checklist, do you think your manuscript has improved? *

yes
no
Other:

Would you like to become involved in the CONSORT EHEALTH group? This would involve for example becoming involved in participating in a workshop and writing an "Explanation and Elaboration" document
O yes
o no
O Other:

Any other comments or questions on CONSORT EHEALTH

Your answer

STOP - Save this form as PDF before you click submit

To generate a record that you filled in this form, we recommend to generate a PDF of this page (on a Mac, simply select "print" and then select "print as PDF") before you submit it.

When you submit your (revised) paper to JMIR, please upload the PDF as supplementary file.

Don't worry if some text in the textboxes is cut off, as we still have the complete information in our database. Thank you!

Final step: Click submit !

Click submit so we have your answers in our database!

Submit

Never submit passwords through Google Forms.

This content is neither created nor endorsed by Google. Report Abuse - Terms of Service - Privacy Policy.

